Prices are updated after-hours

KMPH Treatment Nasdaq

KemPharm Inc

KMPH | $5.46 6.04% 0

(0.0% 1d) (0.7% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 188,396,547
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea treatment profitable

add to watch list Paper trade email alert is off

Press-releases

Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio
Published: 2024-04-10 (Crawled : 09:00) - prnewswire.com
ALPMF | $9.17 16K

Health Technology

| -10.96% | O: -100.0% H: NaN% C: Infinity%
SNYNF | News | $92.7 600K

Health Technology

| -1.65% | O: -0.01% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -2.16% | O: -1.67% H: 0.0% C: 0.0%
ALPMY | $9.47 520K

Manufacturing

| -10.79% | O: -0.29% H: 0.0% C: -1.97%
VTRS | $11.23 0.99% 1.5M

Health Technology

| -5.12% | O: -0.6% H: 1.03% C: 0.52%
TMO | News | $544.01 0.46% 470K

Health Technology

| -9.54% | O: -2.01% H: 0.0% C: 0.0%
NVS | $93.815 1.35% 410K

Health Technology

| -2.71% | O: -1.16% H: 0.0% C: 0.0%
SNY | News | $46.34 2.09% 620K

Health Technology

| -4.25% | O: -0.32% H: 0.0% C: 0.0%
JAZZ | $109.03 -0.22% 66K

Health Technology

| -7.38% | O: -1.71% H: 0.57% C: 0.37%
disorders system set market

Zevra Therapeutics Begins Trading as ZVRA
Published: 2023-03-01 (Crawled : 13:00) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing

| Email alert Add to watchlist
therapeutics

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
Published: 2023-02-27 (Crawled : 22:00) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing

| 0.68% | O: 0.68% H: 0.0% C: 0.0%
rare disease therapeutics

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Published: 2023-02-24 (Crawled : 13:00) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing

| 4.62% | O: 2.04% H: 0.0% C: 0.0%
research therapeutics

CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
Published: 2023-02-22 (Crawled : 14:00) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing

| 10.51% | O: 1.05% H: 4.9% C: 4.53%
change therapeutics

KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
Published: 2023-01-18 (Crawled : 12:20) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing

| 5.65% | O: 7.62% H: 3.67% C: 2.67%
research

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
Published: 2023-01-11 (Crawled : 13:00) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing

| 30.89% | O: 6.44% H: 4.38% C: 3.97%

KemPharm Announces Appointment of Christopher Posner as New Independent Director
Published: 2022-11-29 (Crawled : 13:00) - globenewswire.com
ENDPQ | $0.0006 3.4K

n/a

| -95.92% | O: 1.12% H: 0.1% C: -4.23%
KMPH | $5.46 6.04% 0

Manufacturing

| 24.0% | O: -2.84% H: 0.0% C: 0.0%
BMY | $48.58 0.58% 2.6M

Health Technology

| -38.97% | O: -0.42% H: 0.38% C: 0.28%
CARA | $0.6725 -2.54% 190K

Health Technology

| -93.8% | O: 0.27% H: 0.72% C: -1.25%

KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
Published: 2022-11-18 (Crawled : 13:00) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing

| 24.52% | O: -6.34% H: 0.0% C: 0.0%
treatment fda designation drug

KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
Published: 2022-08-02 (Crawled : 12:00) - globenewswire.com
KMPH | $5.46 6.04% 0

Manufacturing